Options Trading News

December 20, 2012  Thu 7:28 AM CT

Roche Comes Back to the Table

Illumina has been a target of M&A chatter before, and it's back in the headlines today. Swiss newspaper L'Agefi reported that Roche Holding may try to buy the company for $66 a share. ILMN, which closed at $52.17 yesterday, is up 7 percent before the bell on my tradeMONSTER platform.

Motorola Deal Lifts Arris Shares

Arris Group agreed to purchase Motorola Home from Google for $2.35 billion in cash and stock. The deal will also increase ARRS's patent portfolio and give it access to a range of Motorola Mobility's intellectual property. ARRS rose 7 percent in early trading.

Allscripts Down on New Direction

Allscripts Healthcare decided not to sell itself and will instead try to rebuild under new leadership. It fired old CEO and gave the reins to a board member who formerly ran competitor Cerner. The change of direction is sending MDRX down by 16 percent in the premarket.

Amicus Plunges on Drug-Trial Data

Amicus Therapeutics said that its migalastat HCl drug candidate for the treatment of Fabry disease failed to meet goals in a key Phase 3 trial. FOLD craters 45 percent on the news.
Share this article with your friends

Related Stories


Illumina attracts show of support

November 17, 2015

The biosciences stock lost almost half its value between mid-July and early October, hammered by a combination of weak results and bearishness in the space.


Premium Services

Education & Strategy

The art of trading

As I stated in last week's article, a break out or a break down needs to have a couple things happen before it is considered a confirmed break out or break down. The only problem is that in today's market where things move much more quicker than they did just a few years ago, two days could wind up being the majority of the expected movement, if not the whole movement.

View more education articles »